MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Neuro-oncology
- Publicado em
- 1 set 2021
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review
Sebastian Brandner, Alexandra McAleenan, Claire Kelly, Francesca Spiga, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Claire L Faulkner, Christopher Wragg, Sarah Jefferies et al.
Descritores MeSH
- Glioma
- Brain Neoplasms
- Glioblastoma
- Promoter Regions, Genetic
- DNA Modification Methylases
- Antineoplastic Agents, Alkylating
- DNA Methylation
- Tumor Suppressor Proteins
- Temozolomide
- DNA Repair Enzymes
Veja também
Estudos relacionados
- Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
- Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma
- Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis
- A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study